Insurer Green Shield Canada (GSC) reports the results of its biosimilar transition pilot program. Biosimilar transitioning programs are now available for use to all GSC plan sponsors.
Biosimilars Canada has compiled a list of news stories from Canada and abroad about biosimilars that may be of interest to readers. These links to third-party websites are provided for informational purposes only, and do represent an endorsement from our organization. Biosimilars Canada’s statements and news releases are available here.
The Canadian Agency from Drugs and Technology in Health (CADTH) has published an environmental scan of international post-market policies, programs, and other strategies that have been established to guide the uptake of biosimilars and to promote their appropriate and cost-effective use.
Systematic literature review shows low risk of safety concerns or loss of efficacy after switching to a biosimilar
In a review of 90 studies involving 14,255 unique patients the authors found there were no reported increases in treatment-related safety events—including loss of efficacy—related to switching. “Thus, the extensive data collected to date suggest that the act of switching from a reference medicine to a biosimilar is not inherently dangerous, and that patients, healthcare professionals, and the public should not assume that it is problematic,” say the authors.